Decoy Therapeutics (NASDAQ: DCOY) is a biotechnology company developing Designable Multi-Antivirals (D-MAVs™) powered by its proprietary IMP³ACT™ platform. By combining generative AI structural design with advanced peptide-conjugate chemistry, Decoy creates single therapeutics that target conserved viral entry machinery across entire viral families. Decoy’s pipeline includes programs targeting endemic coronaviruses (COVID-19, MERS), paramyxoviruses (RSV, hPIV, Nipah, Measles), and filoviruses (Ebola, Marburg). For more information, visit decoytx.com.